|
Oct 8
|
Bionomics CEO believes company has ‘significant, unrealized value’
|
|
Oct 7
|
Bionomics Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision
|
|
Oct 1
|
Bionomics Limited announces intention to re-domicile to the United States
|
|
Jul 31
|
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder
|
|
Jul 29
|
Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024
|
|
Mar 21
|
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
|
|
Mar 20
|
Bionomics First Half 2024 Earnings: AU$1.62 loss per share (vs AU$2.16 loss in 1H 2023)
|
|
Dec 22
|
Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals
|
|
Dec 6
|
Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting
|
|
Apr 27
|
Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
|